Wall Street analysts expect DURECT Corporation (NASDAQ:DRRX) to post $4.72 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for DURECT Corporation’s earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $7.40 million. DURECT Corporation reported sales of $3.52 million in the same quarter last year, which would indicate a positive year over year growth rate of 34.1%. The firm is expected to report its next earnings results on Tuesday, March 13th.

According to Zacks, analysts expect that DURECT Corporation will report full year sales of $4.72 million for the current year, with estimates ranging from $15.29 million to $24.50 million. For the next fiscal year, analysts forecast that the firm will post sales of $21.05 million per share, with estimates ranging from $12.00 million to $37.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for DURECT Corporation.

DURECT Corporation (NASDAQ:DRRX) last issued its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.09. The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $5.09 million. DURECT Corporation had a negative net margin of 62.57% and a negative return on equity of 638.84%.

A number of equities research analysts have recently weighed in on the stock. HC Wainwright restated a “hold” rating on shares of DURECT Corporation in a report on Thursday. Stifel Nicolaus lowered shares of DURECT Corporation from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. ValuEngine raised shares of DURECT Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Finally, Laidlaw lowered their price objective on shares of DURECT Corporation from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, October 20th.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/11/03/4-72-million-in-sales-expected-for-durect-corporation-drrx-this-quarter.html.

A number of institutional investors have recently modified their holdings of the business. Ingalls & Snyder LLC boosted its holdings in shares of DURECT Corporation by 213.1% in the second quarter. Ingalls & Snyder LLC now owns 6,419,482 shares of the specialty pharmaceutical company’s stock valued at $10,014,000 after acquiring an additional 4,369,400 shares in the last quarter. Asymmetry Capital Management L.P. purchased a new stake in shares of DURECT Corporation in the second quarter valued at about $1,636,000. Tocqueville Asset Management L.P. boosted its holdings in shares of DURECT Corporation by 70.3% in the third quarter. Tocqueville Asset Management L.P. now owns 2,043,383 shares of the specialty pharmaceutical company’s stock valued at $3,617,000 after acquiring an additional 843,383 shares in the last quarter. Stonepine Capital Management LLC boosted its holdings in shares of DURECT Corporation by 13.4% in the second quarter. Stonepine Capital Management LLC now owns 3,175,994 shares of the specialty pharmaceutical company’s stock valued at $4,955,000 after acquiring an additional 374,618 shares in the last quarter. Finally, Mangrove Partners purchased a new stake in shares of DURECT Corporation in the second quarter valued at about $530,000. 45.91% of the stock is currently owned by institutional investors.

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Get a free copy of the Zacks research report on DURECT Corporation (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.